The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Not seen such a great result on any LSE small cap in recent times ! Likely to see a few more RNS’s next week with news of new contracts !!!
De-rampers doing their bit to find a way to get in cheap 🙂
Well done BOD !
GLA
Great RNS yesterday.
On News - https://www.sharecast.com/amp/news/aim-bulletin/botswana-diamonds-discovers-second-anomaly-in-kalahari--16585899.html
GLA
Director’s comments that SP way undervalued !
https://youtu.be/PAGEb2UBpzo?si=eUDKUxYlBebcDFAS
Director’s buy coming in or bid ?
As news flowing in, I think the SP reversal has started. Zak predicted 8 short term and with more news on CIC fda approval SP likely to go back to 25 and higher.
https://www.medicaldevice-network.com/news/uk-nice-backs-use-of-genincodes-test-for-ovarian-cancer-surveillance/
GLA
Octopus increased their holding over 16% in January. They must have done their due diligence on Geni’s projects.
CIC’s fda approval seems to be sure shot considering that it’s a unique polygenic, patended in-vitro diagnostic test used to assess an individuals inherited (DNA) genetic risk of Coronary Heart Disease. The test is based on published clinical evidence amassed over the past 15 years and combined with traditional clinical risk provides a comprehensive risk assessment of Cardiovascular Disease (CVD) for use in primary preventative care.
Still cheap to get in. I would say get in and hold and we will be rewarded, in my view.
I know. It’s fully understandable to keep such things secret at this time to avoid market fluctuations. It’s just my curiosity 😊
From what I have read and seen so far, I don’t have any issue in trusting Geni. I strongly believe it’s going to be a game changer !
GLA
As we know from RNS dated 19/07/23, Geni is working in partnership with Medstar heath in US trialing CIC. I was looking for updates, but can’t find much info. I have seen a link about them opening clinics, but I can’t open the link.
https://www.baltimoresun.com/2024/03/04/medstar-patient-centered-focus-cardiovascular-outpatient-center/
Zak predicts 8.1 short term
https://youtu.be/mugBaGF0u_M
My view is that, it’s not a dream or guess anymore. The NICE assessment/ recommendation of ROCA is just the beginning. In terms of CIC-Score, FDA’s initial assessment was that it’s ‘first in class' position and have deep clinical evidence for polygenic risk assessment of CHD’. Hence, asked to submit under De Novo pathway.
As you may know, The De Novo request provides a marketing pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device.
Bright days ahead in my view 🙌
GLA
Momentum building. Geni all over the media with news from yesterday.
https://www.medicaldevice-network.com/news/uk-nice-backs-use-of-genincodes-test-for-ovarian-cancer-surveillance/
Hope we will get to see the FDA approval news on Monday ! GLA
Huge re-rate chances here 🚀🚀🚀🚀🚀
FDA approval news due anytime. See below from RNS dated
Following the CARDIO inCode-Score 510(k) medical device submission in August 2023, the FDA has reviewed the submission and recently noted CARDIO inCode-Score's 'first in class' position and the deep clinical evidence for polygenic risk assessment of CHD. Based on these factors and the novel position of CARDIO inCode-Score, the FDA has requested the Company to transition to a De Novo pathway for market approval. The crossover to a De Novo pathway enables the Company to work with the FDA to establish a new polygenic regulatory class for the CARDIO inCode-Score medical device based on its favourable benefit-risk profile and associated special controls thereby setting a new regulatory standard for future polygenic tests in this class. Following the FDA request, the Company has now submitted its De Novo submission for market clearance and expects a timeline to clearance broadly in line with earlier the earlier 510(k) submission forecasts of late Q1/early Q2 2024.
First US revenue news also due !
Check the link below; found on X
https://x.com/buoyant_recluse/status/1770816631490462110?s=46&t=WuyCAqCnuctRxVwyXpOFyg
Warming up nicely! GLA 🙌